279 related articles for article (PubMed ID: 23549037)
1. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Zhang L; Liu T; Zhang JQ
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):212-6. PubMed ID: 21575522
[TBL] [Abstract][Full Text] [Related]
3. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
5. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
7. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
9. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Ke HG; Li J; Shen Y; You QS; Yan Y; Dong HX; Liu JH; Shen ZY
Asian Pac J Cancer Prev; 2012; 13(9):4413-6. PubMed ID: 23167352
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Ann Oncol; 2010 Sep; 21(9):1817-1824. PubMed ID: 20332140
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract][Full Text] [Related]
16. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
17. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
19. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
